Literature DB >> 11122727

Complete and selective estrogenic effects on lipids and cardiovascular disease.

S Lamon-Fava1.   

Abstract

Observational studies have shown a protective effect of estrogen replacement on risk of cardiovascular disease in postmenopausal women. The estrogen protection is thought to be mediated by mechanisms acting at different levels, including a beneficial effect on plasma lipid concentrations. Selective estrogen receptor modulators (SERM) share with estrogen the ability to reduce plasma levels of atherogenic lipoproteins like low-density lipoproteins and lipoprotein(a). The recent publication of the first randomized, placebo-controlled trial of estrogen/progestin replacement (HERS), which failed to show a reduced number of cardiovascular events in women randomized to estrogen treatment as compared with placebo, has cast some doubts on the protective role of estrogen. Other large randomized studies on the effect of estrogen and other compounds with estrogenic activity (eg, SERM) on cardiovascular disease risk are currently underway and will provide more definite answers to both clinicians and postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122727     DOI: 10.1007/s11883-000-0097-x

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.967


  29 in total

1.  Postmenopausal hormone therapy--good for smokers?

Authors:  D Grady
Journal:  J Am Coll Cardiol       Date:  1999-07       Impact factor: 24.094

Review 2.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

3.  Postmenopausal use of estrogen and occlusion of coronary arteries.

Authors:  H W Gruchow; A J Anderson; J J Barboriak; K A Sobocinski
Journal:  Am Heart J       Date:  1988-05       Impact factor: 4.749

4.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

Authors:  P D Delmas; N H Bjarnason; B H Mitlak; A C Ravoux; A S Shah; W J Huster; M Draper; C Christiansen
Journal:  N Engl J Med       Date:  1997-12-04       Impact factor: 91.245

5.  Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

Authors:  B W Walsh; L H Kuller; R A Wild; S Paul; M Farmer; J B Lawrence; A S Shah; P W Anderson
Journal:  JAMA       Date:  1998-05-13       Impact factor: 56.272

6.  The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women.

Authors:  M R Soma; I Osnago-Gadda; R Paoletti; R Fumagalli; J D Morrisett; M Meschia; P Crosignani
Journal:  Arch Intern Med       Date:  1993-06-28

Review 7.  Chylomicronemia syndrome.

Authors:  A Chait; J D Brunzell
Journal:  Adv Intern Med       Date:  1992

8.  Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women.

Authors:  M Weintraub; I Grosskopf; G Charach; N Eckstein; A Rubinstein
Journal:  Metabolism       Date:  1999-09       Impact factor: 8.694

9.  Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women.

Authors:  F Grodstein; M J Stampfer; M Falkeborn; T Naessen; I Persson
Journal:  Epidemiology       Date:  1999-09       Impact factor: 4.822

10.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.